Zinc finger protein 382 is downregulated by promoter hypermethylation in pediatric acute myeloid leukemia patients.

Int J Mol Med 2014 Dec 13;34(6):1505-15. Epub 2014 Oct 13.

Department of Hematology and Oncology, Children's Hospital of Soochow University, Suzhou, Jiangsu, P.R. China.

Acute myeloid leukemia (AML) is the second-most common form of leukemia in children. Aberrant DNA methylation patterns are characteristic of AML. Zinc finger protein 382 (ZNF382) has been suggested to be a tumor suppressor gene possibly regulated by promoter hypermethylation in various types of human cancer. However, ZNF382 expression and methylation status in pediatric AML is unknown. In the present study, ZNF382 transcription levels were evaluated by quantitative reverse-transcription PCR. Methylation status was investigated by methylation-specific (MSP) PCR and bisulfate genomic sequencing (BGS). The prognostic significance of ZNF382 expression and promoter methylation was assessed in 105 cases of pediatric AML. The array data suggested that the ZNF382 promoter was hypermethylated in the AML cases examined. MSP PCR and BGS analysis revealed that ZNF382 was hypermethylated in leukemia cell lines. Furthermore, treatment with 5-aza-2'-deoxycytidine (5-Aza) upregulated ZNF382 expression in the selected leukemia cell lines. The aberrant methylation of ZNF382 was observed in 10% (2/20) of the control samples compared with 26.7% (28/105) of the AML samples. ZNF382 expression was significantly decreased in the 105 AML patients compared with the controls. Patients with ZNF382 methylation showed lower ZNF382 transcript levels compared with patients exhibiting no methylation. There were no significant differences in clinical characteristics or cytogenetic analysis between the patients with or without ZNF382 methylation. ZNF382 methylation correlated with minimal residual disease (MRD). Kaplan-Meier survival analysis revealed similar survival times in the samples with ZNF382 methylation, and multivariate analysis revealed that ZNF382 methylation was not an independent prognostic factor in pediatric AML. The epigenetic inactivation of ZNF382 by promoter hypermethylation can be observed in AML cell lines and pediatric AML samples. Therefore, our study suggests that ZNF382 may be considered a putative tumor suppressor gene in pediatric AML. However, further studies focusing on the mechanisms responsible for ZNF382 downregulation in pediatric leukemia are required.

Download full-text PDF

Source
http://dx.doi.org/10.3892/ijmm.2014.1966DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4214337PMC
December 2014
56 Reads

Publication Analysis

Top Keywords

znf382 methylation
20
pediatric aml
20
znf382
18
znf382 expression
16
cell lines
12
analysis revealed
12
promoter hypermethylation
12
aml
11
methylation
11
samples znf382
8
aml samples
8
myeloid leukemia
8
tumor suppressor
8
revealed znf382
8
leukemia cell
8
suppressor gene
8
acute myeloid
8
methylation znf382
8
patients znf382
8
methylation status
8

Similar Publications